Key statistics dashboard for Keros Therapeutics, Inc. (KROS). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options.
Stock Data
| Price | $10.74 |
| Market Cap | $344M |
| Beta | 0.99 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -2.91 |
| Price / Book | 0.81 |
| P/S | 22.91 |
| P/FCF | -7.09 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 94.68% |
| EBIT Margin | -573.44% |
| EBITDA Margin | -562.79% |
| Operating Margin | -675.82% |
| Net Margin | -553.88% |
Financial Health
| Current Ratio | 21.96 |
| Quick Ratio | 21.96 |
| Cash Ratio | 21.20 |
| Debt / Equity | 0.06 |
| Debt / Assets | 5.47% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.76 |
| Book Value per share | 13.25 |
| Cash per share | 13.01 |
| FCF per share | -2.45 |
| Tangible Book Value per share | 13.25 |
| Dividend per share | 0.00 |
Related companies: ABSI · CRVS · CTMX · MLTX · NAGE · OLMA · RGNX
Explore sector: Healthcare · Biotechnology
More sections of KROS: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks